DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026)

DBV Technologies (DBVT) posted quarterly Income towards Parent Company of -$50.4 million for Q2 2026, down 20.29% year-on-year from -$63.2 million in Q2 2025, and down 5.88% on a QoQ basis from -$47.6 million in Q1 2026.

DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026) Analysis & Trends

DBV Technologies (DBVT) has reported Income towards Parent Company for 7 consecutive years, with -$50.4 million the latest figure, recorded in Q2 2026.

  • Quarterly Income towards Parent Company fell 20.29% year-over-year to -$50.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$176.0 million (down 43.72% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
  • Income towards Parent Company fell to -$50.4 million in Q2 2026 per DBVT's latest filing, from -$47.6 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for DBVT reached as high as -$11.2 million in Q4 2023 and fell as low as -$50.4 million in Q2 2026.
  • A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 187.02% — and 2023, when it jumped 71.49%.
  • Year by year, Income towards Parent Company stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then slumped by 105.75% to -$23.0 million in 2024, then slumped by 94.78% to -$44.8 million in 2025, then slipped by 12.43% to -$50.4 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$50.4 million, -$47.6 million, and -$44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn
7 Belite Bio 62.84 Bn 62.84 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 DBV Technologies 5.99 Bn 5.82 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 -50.40 Mn
Mar 31, 2026 -47.60 Mn
Dec 31, 2025 -44.83 Mn
Sep 30, 2025 -33.16 Mn
Jun 30, 2025 -41.90 Mn
Mar 31, 2025 -27.10 Mn
Dec 31, 2024 -23.02 Mn
Sep 30, 2024 -30.44 Mn
Jun 30, 2024 -33.12 Mn
Mar 31, 2024 -27.35 Mn
Dec 31, 2023 -11.19 Mn
Sep 30, 2023 -16.74 Mn
Jun 30, 2023 -24.24 Mn
Mar 31, 2023 -20.56 Mn
Dec 31, 2022 -39.24 Mn
Sep 30, 2022 -17.29 Mn
Jun 30, 2022 -23.04 Mn
Mar 31, 2022 -16.71 Mn
Dec 31, 2021 -13.67 Mn
Sep 30, 2021 -24.03 Mn